Brigatinib in NF2-Related Schwannomatosis

Vivek Subbiah shared on X:

“Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors.

• NF2-related schwannomatosis (NF2-SWN, formerly called neurofibromatosis type 2) is a tumor predisposition syndrome that is manifested by multiple vestibular schwannomas, nonvestibular schwannomas, meningiomas, and ependymomas.
• The condition is relentlessly progressive with no approved therapies.
• On the basis of preclinical activity of brigatinib (an inhibitor of multiple tyrosine kinases) in NF2-driven nonvestibular schwannoma and meningioma, data were needed on the use of brigatinib in patients with multiple types of progressive NF2-SWN tumors.
• Radiographic response was 10% for target tumors and 23% (95% CI, 16 to 30) for all tumors.
• Hearing improvement occurred in 35% (95% CI, 20 to 53) of eligible ears.”

Additional information.
Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.